QuestionComment
Does the calculated curve go near the data points?If the curve doesn't go near the data, then something went wrong with the curve fit, and the "best-fit" values of Bmax and Kd should be ignored.
Were sufficient concentrations of radioligand used?Ideally, the highest concentration should be at least 10 times the Kd. Calculate the ratio of the highest radioligand concentration used divided by the Kd reported by the program (both in nM or pM). The ratio should be greater than 10.
Is the Bmax reasonable?Typical values for Bmax are 10 to 1000 fmol binding sites per milligram of membrane protein, 1000 sites per cell, or 1 receptor per square micron of membrane. If using cells transfected with receptor genes, then the Bmax may be 10 to 100 times larger than these values.
Is the Kd reasonable?Typical values for Kd of useful radioligands range between 10 pM and 100 nM. If the Kd is much lower than 10 pM, the dissociation rate is probably very slow and it will be difficult to achieve equilibrium. If the Kd is much higher than 100 nM, the dissociation rate will probably be fast, and may result in the loss of binding sites during separation of bound from free radioligand.
Are the standard errors too large? Are the confidence intervals too wide?Nonlinear regression programs report the uncertainty of the best-fit values for Bmax and Kd as standard errors and 95% confidence intervals. Divide the SE of the Bmax by the Bmax, and divide the SE of the Kd by the Kd. If either ratio is much larger than ~20%, look further to determine why.
Is the nonspecific binding too high?Divide the nonspecific binding at the highest concentration of radioligand by the total binding at that concentration. Nonspecific binding should usually be less than 50% of the total binding.

Table 7.5.2 Evaluating the Assumptions of Saturation Binding Analysis

AssumptionComment
Binding has reached equilibrium.It takes longest for the lower concentrations to equilibrate, so test equilibration time with the lowest concentration of radioligand.
There is only one population of receptors.See Theory: Comparing One- and Two-Site Models, below.
Only a small fraction of the radioligand binds, therefore the free concentration is essentially identical to the concentration added.Compare the cpm obtained for total binding to the amount of ligand. If the ratio is greater than 10% at any concentration, this assumption has been violated. Increase the volume of the reaction but use the same amount of tissue.
There is no cooperativity. Binding of a ligand to one binding site does not alter the affinity of another binding site.See Cooperativity, below.

Preclinical support

proteomics
Goal
Support biology for MC1 PET
Back up (mitigation) of ps65-ub
Activity of mitochondria (?)Outer memb (tom 40/2 substrate (vdac) Fission (drp1)
Cell prep: see (Kazami, 2019 #1082), PhReT proposal
Radioligand binding study
  • 3월에 MJFF 성공하면 → 그래도 PE후로 기다리니?, ARG도 불필요하지 않니?
  • 3월에 MJFF 실패하면 → PE후로 기다리야겠지. ARG 필요하려나?

Fibroblasts

  • PARK2 cells: originally obtained by Matsui-san (ARNU) and Uno-san (EONU) from NINDS. → distributed to NS-DDU, and at least Yamaguchi-san (ARNU) and I currently maintain the stocks
identifiervendorAgegenderOnset ageDxH&Y stageUPDRS total / motor scoreMMSEPassage at freeze
106-05a(cell applications →) ToyoboAdultCould not expand, not fibro-ish morphology
106-05n(cell applications →) ToyoboNeonatal
CC-2511Lonza45
C-12302PromocellAdult (셋 중 하나 lot#를 알아야 함)Could not expand, not fibro-ish morphology
C-1230227femalecaucasian448Z024.3>20
C-1230228femalecaucasian467Z026.3>20
C-1230278femalecaucasian455Z026.116
GM01650Coriell37F10
GM03652Coriell24M
Parkin-PD
11ND31618,NINDS63F44ARG42PRO (R42P) Heterozygus2.028NA5
11ND30171,NINDS54M42ARG42PRO (R42P), EX3DEL Compound Heterozygous2.0302
12ND40078NINDS51F46ARG275TRP/ARG275GLN, (R275W/R275Q) Compound Heterozygous2.031.5 (on)11
6.07
ND29369NINDS61F43ARG275TRP (R275W) Heterozygous (빼자)3.0292

NINDS에서 excel을 Download받아놓았음, 약 35명, to do:major variant에 sequencing 한 결과인지? 20210602 order ID is NHCDR-000840

sPD

cryopreservationFibroblast IDs (=submitter tube label)Subject IDGenderageAAOAge at DxDurationH&yraceSubmitter_PassageSubmitter_Concentration
box2, Colum1 ack A1, bigger N2 tank DR-430LM, B13F-3140ND37609NINDSNDS00051M68526532Caucasian3505555
ND35302NINDSNDS00040M695858112Caucasian2573333
ND37132NINDSNDS00048M66606062Caucasian2516666
ND30159NINDSNDS00014F76727422Caucasian2502000
identifierAgegenderOnset ageH&Y stageMMSE
106-05nNeonatal
CC-251145
GM0165037F
GM0365224M
ND31618 R42P, homozygous63F442.028
ND30171 R42P/EX3DEL, Compound heterozygous54M422.030
ND40078 R275W/R275Q, Compound heterozygous51F462.0
ND29369 R275W, Heterozygous61F433.029
  • lines 12 ?
  • pool ; purpose, reason to believe, average anyway
  • The line is now under expansion culture with around 30 flasks (expected protein is around 9 mg) and if we decide to expand further, the flask number will be around 100.
zoneDiseaseVendorNumberGenderAge samplingAge diagnosisAge onsetRaceCountryFamily HistoryGenetic DataHoehn and Yahr stageMMSE
3Healthy controlCoriellGM01650F37Caucasian
4Healthy controlCoriellGM03652M24Caucasian
6Healthy controlCell App106-05nNeonatal
8Healthy controlLonzaCC-2511F45
0Parkinson's diseaseNINDSND31618F634644CaucasianUSAR42P2
1Parkinson's diseaseNINDSND30171M544342CaucasianUSAabsentR42P/EXON3del2
2Parkinson's diseaseNINDSND40078F514746CaucasianSWEDENMaternal auntR275W/R275Q cmpd2
3Parkinson's diseaseNINDSND29369F614443OtherDOMINICAabsentR275W het3
DiseaseVendorNumberGenderAge samplingAge diagnosisAge onsetRaceCountryFamily HistoryGenetic DataHoehn and Yahr stageMMSE
Healthy controlCoriellGM01650F37Caucasian
CoriellGM03652M24Caucasian
Cell App106-05nNeonatal
LonzaCC-2511F45
Park2-PDNINDSND31618F634644CaucasianUSAR42P2
NINDSND30171M544342CaucasianUSAabsentR42P/EXON3del2
NINDSND40078F514746CaucasianSWEDENMaternal auntR275W/R275Q cmpd2
NINDSND29369F614443OtherDOMINICAabsentR275W het3

Uncertain Spans

locationtranscriptionuncertainty
Q&A table / Comment cellspreserved with verbatim yellow highlighting; the highlight in source overlaps multiple sentences.low confidence on the exact extent of the highlight in nested tokens.
Fibroblasts inventory / faint-text rowsrows for 106-05a / 106-05n / CC-2511 / C-12302 / GM01650 / GM03652 are rendered in faint grey in the source (likely “deprecated/no-data” rows); preserved verbatim in normal text style.grey-text styling is dropped in this rendering; row data preserved.
Parkin-PD / ND40078 row / Passage at freeze cellsreads 11 and 6.07 stacked in a single cell in the source; preserved as <br>-separated lines.low confidence on whether 6.07 is a passage value, mass, or a separate annotation.
Cryopreservation row 1 left columnreads box2, Colum1 ack A1, bigger N2 tank DR-430LM, B13F-3140 reconstructed from partial OCR box2, Colum1 / ack A1, bigger / N2 tank DR-430LM, / B13F-3140.freezer-location label reconstructed from visible fragments.
Bottom red-banded second copy / zone columnleft-most column header zone is partially obscured by the previous row band; preserved verbatim.column boundary partly clipped.